RG Lucae: Psychiatric Pharmacogenetics
Max Planck Institute of Psychiatry
Antidepressants represent the most effective treatment for patients suffering from major depression. However, only about 60 % of depressed patients respond sufficiently to their first treatment. So far, little is known about the factors determining treatment outcome. It is the aim of this research group to investigate the interplay between psychopathology, neuroendocrine and metabolic changes as well as genetic variability in order to elucidate the processes contributing to a successful treatment outcome in depressed patients.